



**Paschal Uchehara**

Taylor Award  
Chemistry Major  
First Year ARCS Scholar



**MOREHOUSE**  
COLLEGE

# Selective Biological Activity of IL-2 Immunocytokines: A Focus on Effector Immune Cell Populations and Cancer Treatment

Human interleukin-2 (hIL-2) has limited clinical applications due to its short in vivo half-life and preferential activation of regulatory T (Treg) cells over immune effector cells (Eff). The F10 immunocytokine (IC) collagen binding domain (CBD), a fusion protein of hIL-2 and mouse antibody, extends hIL-2's half-life, reducing Treg activation, and enhances effector cell stimulation, showing promise for improved anti-tumor efficiency in cancer immunotherapy.

